US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BioStock: Mendus steps up the clinical development in 2023

Mendus released its 2022 Annual Report this week, which refers to 2022 as a “breakthrough” year for the company. The milestones reached give Mendus the opportunity to prepare vididencel for the next phase of clinical development, reinitiate clinical development with its intratumoral primer ilixadencel, and make way for a new pipeline programme in the upcoming field of NK cell therapies. BioStock spoke with CEO Erik Manting to learn moreRead the interview with Erik Manting at biostock.se: Mendus steps up the clinical development in 2023 - BioStock 

BioStock: Mendus presents NK cell data at the Annual Innate Killer Summit

Mendus has presented additional data highlighting the use of its proprietary DCOne platform for the ex vivo expansion of NK cells, at the 8th Annual Innate Killer Cell Summit in La Jolla, San Diego. The presentation stresses the fact that DCOne cells drive strong expansion of memory NK cells, as a basis for potential new NK cell-based cancer therapies.Read the article at biostock.se: Mendus presents NK cell data at the Annual Innate Killer Summit - BioStock This is a press release from

BioStock: Mendus presents proof-of-concept data in AML maintenance

Acute myeloid leukaemia relapses easily, leading to a significant decrease in survival chances. Immuno-oncology biotech Mendus is developing a tumour recurrence vaccine, and new positive phase II data presented yesterday at the American Society of Hematology meeting suggest that the company’s candidate DCP-001 is much more effective than current standard of care AML maintenance treatment.Read the article at biostock.se: Mendus presents proof-of-concept data in AML maintenance - BioStock 

BioStock: Mendus nears late-stage development with cancer relapse vaccine

Tumour recurrence is the underlying cause of the majority of cancer deaths worldwide. Tackling the issue is immuno-oncology company Mendus with the development of relapse vaccine DCP-001. Encouraging data has come from both a phase II trial in acute myeloid leukeamia and a phase I trial in ovarian cancer, which has been accompanied by funding by the European Commission as well as landing a manufacturing agreement aimed at late-stage and commercial production of DCP-001. Key survival data updates from the phase II study in AML are expected during Q4 this year.Read the article at biostock.se:

BioStock: Mendus in strong position for clinical progress

Q2 brought key milestones to immuno-oncology company Mendus. Preclinical as well as clinical results related to cancer relapse vaccine DCP-001 have set the company up for  potential significant advancements in the clinic in the coming months. Additionally, a strengthened management team and a corporate rebranding also came in Q2, suggestive of a company with a renewed confidence in its aim to bring better treatments to cancer patients. BioStock reached out to Mendus’s CEO Erik Manting to get his thoughts on the past quarter and what lies ahead for the company.Read the interview with Erik

BioStock: Immunicum changes name to Mendus

The biotech company previously known as Immunicum is now operated and traded under the name Mendus. The company, that develops immunotherapies for cancer patients with tumour recurrence, believes that the new name reflects its maturity and its long-term ambitions.Read the article at biostock.se: https://www.biostock.se/en/2022/06/immunicum-changes-name-to-mendus/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

BioStock: Immunicum delivers positive phase II data in AML

Swedish/Dutch biotech Immunicum has been taking huge strides towards its goal of delivering a new treatment for one of the most serious challenges within cancer therapy: tumour recurrence. The latest step forward came earlier this week in the form of positive interim phase II data from the company ADVANCE-II project in acute myeloid leukaemia patients.Read the article at biostock.se: https://www.biostock.se/en/2022/05/immunicum-delivers-positive-phase-ii-data-in-aml/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

BioStock: Immunicum to present data for potential AML treatment

Acute myeloid leukaemia has one of the highest rates of recurrence after initial remission, and treatment options are limited. Immuno-oncology company Immunicum is addressing the issue by developing a cancer relapse vaccine, DCP-001. The company will present positive preclinical data at the CIMT meeting suggesting that DCP-001 works in synergy with conventional acute myeloid leukemia treatments to amplify the therapeutic effects. In parallel, the company is also on schedule to present novel clinical data on DCP-001 as a monotherapy later this quarter.Read the article at biostock.se:

BioStock: Immunicum participates in new cancer research consortium

In an effort to bring new cancer treatments faster to patients, the Dutch National Growth Fund will support a new cancer research consortium called Oncode-PACT with 325 MEUR. Cancer therapy biotech Immunicum has announced being part of the consortium, contributing with its expertise in dendritic cell biology to design novel cancer immunotherapies.Read the article at biostock.se: https://www.biostock.se/en/2022/04/immunicum-participates-in-new-cancer-research-consortium/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

BioStock: Immunicum’s strategy for fighting tumour recurrence

Tumour recurrence is the underlying cause of the majority of cancer deaths worldwide. It is thus considered one of the most pressing challenges within the oncology field. Swedish immuno-oncology company Immunicum is addressing this challenge with relapse vaccine candidate DCP-001, which is currently in phase II clinical stage. BioStock takes a closer look.Read the full article at biostock.se: https://www.biostock.se/en/2022/03/immunicums-strategy-for-fighting-tumour-recurrence/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Immunicum can look back on a transformative 2021

Following the merger with DCprime in late 2020, Swedish cancer immunotherapy company Immunicum has built an advanced clinical pipeline addressing two major challenges in oncology: hard-to-treat solid tumours and tumour recurrence. BioStock reached out to Immunicum’s CEO Erik Manting to get his thoughts on the company’s achievements during 2021 and what to expect from Immunicum in 2022.Read the interview with Immunicum's CEO Erik Manting at biostock.se: https://www.biostock.se/en/2022/01/immunicum-can-look-back-on-a-transformative-2021/ This is a press release from BioStock -

BioStock: Immunicum finalises phase I ILIAD trial

Immunicum’s phase Ib ILIAD project was designed to evaluate ilixadencel across a broad range of cancer indications and in combination with the anti-PD1 checkpoint inhibitor pembrolizumab. The company has announced completing the project after conducting a positive safety and response evaluation, and Immunicum has decided not to pursue a phase II portion of the trial. BioStock spoke with CEO Erik Manting to learn more about the results and the decision-making around phase II.Read the interview with Immunicum's CEO Erik Manting at biostock.se: https://www.biostock.se/en/2021/12/immunicum-

BioStock: Immunicum publishes DCP-001 data

Thanks to the merger with DCPrime, Swedish immuno-oncology company Immunicum added DCP-001 to its clinical development programme – a cancer relapse vaccine aimed at preventing tumour recurrence. The candidate is currently in the phase II programme in patients with acute myeloid leukaemia, and, this week, the company has announced the publication of a scientific journal article describing the mechanism of action for DCP-001. The data shows that the cancer relapse vaccine provides active immunization and a durable anti-tumour immune response.Read the article at biostock.se 

BioStock: Immunicum’s vision for the cancer therapy landscape

Two of the biggest challenges in oncology are hard-to-treat solid tumours and tumour recurrence. Swedish biotech Immunicum are on a mission to tackle both challenges through their two cell-based immunotherapy candidates, ilixadencel and DCP-001. BioStock takes a closer look at the cancer therapy landscape and how Immunicum plans to make an impact.Read the article at biostock.se : https://www.biostock.se/en/2021/11/immunicums-vision-for-the-cancer-therapy-landscape/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.

BioStock Studio: Immunicum’s CEO on the company’s new therapeutic focus

Swedish immunotherapy company Immunicum has broadened its cancer treatment focus with the addition of drug candidate DCP-001 thanks to the merger with Dutch biotech DCprime. Treating tumour recurrence is now a top priority for the company, and Immunicum’s CEO Erik Manting came by the BioStock Studio to talk more in depth about this new focus and how the addition of DCP-001 impacts Immunicum’s business strategy.Watch the interview with Erik Manting at biostock.se: https://www.biostock.se/en/2021/09/biostock-studio-immunicums-ceo-on-the-companys-new-therapeutic-focus/ This is a press

BioStock: Immunicum aiming for new heights within immuno-oncology

Thanks to the merger with DCprime, Swedish immuno-oncology company Immunicum has built a solid foundation for becoming an integrated, international organization with an advanced clinical pipeline.  Following the release of the company’s Q2 report, BioStock reached out to Immunicum’s CEO Erik Manting to get his view on the company’s main goals and what to expect from Immunicum during the rest of 2021.Read the interview with Immunicum's CEO Erik Manting at biostock.se: https://www.biostock.se/en/2021/09/immunicum-aiming-for-new-heights-within-immuno-oncology/ This is a press release

BioStock Studio: Immunicum and DCprime enter immuno-oncology merger

Swedish Immunicum announced last week that it has entered into an agreement with Van Herk Investments to acquire all of the shares in DCprime, a Dutch clinical stage company developing cancer relapse vaccines aimed to reduce tumor recurrence. The goal of the merger is to establish global leadership in developing cell-based cancer immunotherapies. BioStock was able to link up with Immunicum’s CEO, Sven Rohmann, as well as DCprime’s CEO, Erik Manting, for virtual video interview to learn more about the big news.Watch the full interview with Sven Rohmann and Erik Manting at biostock.se:

BioStock: Immunicum updates clinical development strategy

Since bringing in Sven Rohmann as new CEO in August, Immunicum has updated its clinical development strategy to include four major pillars aimed at delineating the best way to market. In addition, the company presented positive preclinical data at ESMO 2020 last month, showing that the its off-the-shelf immuno-oncology treatment ilixadencel strengthens the efficacy of existing immunotherapies.Read the full article at biostock.se: https://www.biostock.se/en/immunicum-updates-clinical-development-strategy/ This is a press release from BioStock - Connecting Innovation & Capital. https://

BioStock: New CEO brings deal-making experience to Immunicum

Last month, Swedish biotech Immunicum announced the recruitment of a new CEO, Sven Rohmann. The change in leadership comes at an opportune time for the company, when partnering is on the horizon, and Rohmann’s extensive business development experience will be of great value to the company. BioStock was able to get in touch with the new CEO to get a sense of his vision for Immunicum.Read the full interview with Sven Rohmann at biostock.se: https://www.biostock.se/en/new-ceo-brings-deal-making-experience-to-immunicum/ This is a press release from BioStock - Connecting Innovation &

BioStock: Immunicum announces MERECA trial update

Immunicum’s phase II MERECA study testing ilixadencel in kidney cancer patients is entering the final stretch. Yesterday, the company announced an update on the study that seems to indicate that their candidate is providing a survival benefit to patients. BioStock reached out to Immunicum’s COO Sijme Zeilemaker to learn more.Read the full interview with Sijme Zeilemaker at biostock.se: https://www.biostock.se/en/immunicum-announces-mereca-trial-update/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se 

BioStock: Immunicum gears up for second half of 2020

2020 has so far been a transition year for Immunicum. While continuing their progress with the Phase II MERECA study and Phase Ib/II ILIAD study, they have received RMAT designation from the FDA for their top drug candidate ilixadencel. Recently, the immuno-oncology company also received feedback from both the FDA and EMA to further support preparations of the next steps in development. BioStock spoke with Immunicum’s Interim CEO Alex Karlsson-Parra to look back at the year so far and see what is in the books for the rest of the year.Read the full interview with Alex Karlsson-Parra at

BioStock: Immunicum’s immuno-oncology platform shares the spotlight at Cancer Progress conference

The field of immuno-oncology encompasses several strategies to push our own immune system to be more sensitive and reactive to cancer cells and metastases. Swedish biotech Immunicum have developed their own strategy and were asked to present and discuss it on a panel of immuno-oncology experts at the 31st Annual Cancer Progress Conference last week. BioStock caught up with Immunicum’s COO, Sijme Zeilemaker, who represented the company on that panel, to learn more about the discussion and how Immunicum is making a difference in the field.Read the full interview with Sijme Zeilemaker at

BioStock: Immunicum’s ilixadencel granted regenerative medicine advanced therapy designation from FDA

Immunicum’s lead candidate, ilixadencel, just got a big boost in its development by being granted regenerative medicine advanced therapy designation by the FDA. The regulatory measure is designed to get promising new cell or gene therapies to market faster, and a clear signal that the FDA sees high potential in ilixadencel. BioStock reached out to Immunicum’s COO Sijme Zeilemaker to learn more about the news and what it means for ilixadencel moving forward.Read the full interview with Sijme Zeilemaker at biostock.se: https://www.biostock.se/en/immunicums-ilixadencel-granted-regenerative-

There are no items matching the current filter
There are no more items matching the current filter
Back to top